Safety, and Tolerability
27
2
3
20
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.4%
2 terminated out of 27 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
30%
6 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (27)
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
Phase 1 Clinical Study of JMKX003142 Tablets
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
A Phase I Pharmacokinetics Study for KT07 Capsule
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD